We are thrilled to announce that Pocus has successfully raised $23 million in our latest funding round, spearheaded by prominent investors who share our vision of transforming the sales landscape through cutting-edge technology. Pocus is committed to enabling go-to-market teams to build pipeline and close revenue consistently by streamlining workflows with our AI-powered platform. Our solution enhances prospecting, research, and playbook optimization, allowing sales representatives to focus on what they do best: selling. The funds raised in this round will be instrumental in accelerating our product development and expanding our reach to even more teams and organizations. With Pocus, esteemed companies like Asana, Canva, Miro, and Loom are already experiencing significant benefits; many users report saving over 10 hours a week that would otherwise be spent sifting through data. This funding will enable us to enhance our robust capabilities further and empower more teams to implement the right go-to-market playbooks powered by AI. As we embark on this exciting new chapter, we remain dedicated to our mission of helping teams transform their sales strategies from siloed efforts to cohesive and streamlined operations. Thank you to our investors, partners, and users for believing in our vision鈥攚e are excited to lead the charge in revolutionizing revenue generation for teams everywhere.
Pocus Secures $23 Million in Funding to Revolutionize Go-To-Market Strategies with AI-Powered Solutions
Recently funded 路 $23.0MSales Platform
Get the full Pocus company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Xentra
From cyber security, through to safeguarding and compliance, we provide digital security solutions perfectly designed to suit any requirement. Our team of experts will help you assess, select and implement the right solutions for your organisation; setting you up for success and helping you deliver against key objectives. We pride ourselves on understanding the digital security landscape, thoroughly evaluating available technologies and building long-term partnerships with our customers. We don鈥檛 believe in quick fixes. Whether you require a point solution to tackle a single requirement, or would benefit from a complete managed service, our solutions are built to stand the test of time. Since 2020, we鈥檝e been helping organisations such as Leeds United Football Club, Thomas鈥檚 London Day Schools, Setfords, JT Atkinson and Northern Estate Agencies Group, manage and optimise their overall digital security. Along the way, we have set the standard for what a customer-first approach to digital security looks like, and how to measure success.
$3.5M Series a
today
Estrigenix Therapeutics, Inc.
Estrigenix Therapeutics, Inc. is a privately held pharmaceutical company developing the next generation of innovative therapies for improving the mental health of menopausal women. Menopause is associated with cognitive dysfunction, increased mood and anxiety disorders, and an elevated risk of Alzheimer鈥檚 disease, yet standard estrogen therapies are associated with increased risks of cancer, heart disease, and stroke. Our mission is to develop novel drugs that mitigate the adverse effects of menopause on mental health and enable women to live healthier and happier lives. The drug development program at Estrigenix focuses on selectively activating specific estrogen receptor proteins that promote memory formation, improve mood, and reduce anxiety. We believe that targeting these receptors will provide the cognitive and mood-enhancing benefits of estrogens without the harmful side effects of standard estrogen therapies. Our lead compound, EGX-358, is a potent and selective agonist of the estrogen receptor beta protein, which enhances memory formation in a mouse model of menopause. Current work is expanding the use of this compound to other indications, including depression, anxiety, and hot flashes.
